Invasive Candida infections remain an important cause of morbidity and mortality, especially
in hospitalized and immunocompromised or critically ill patients. A limited number of …

Antifungal resistance represents a major clinical challenge to clinicians responsible for
treating invasive fungal infections due to the limited arsenal of systemically available …

Invasive candidiasis is an important fungal disease caused by Candida albicans and,
increasingly, non-albicans Candida pathogens. Invasive Candida infections originate most …

Background. Fluconazole (FLC) resistance is common in C. glabrata and echinocandins are
often used as first-line therapy. Resistance to echinocandin therapy has been associated …

Invasive fungal infections are an important infection concern for patients with underlying
immunosuppression. Antifungal therapy is a critical component of patient care, but …

Human fungal pathogens are attributable to a significant economic burden and mortality
worldwide. Antifungal treatments, although limited in number, play a pivotal role in …

Fungal infections due to Candida and Aspergillus species cause extensive morbidity and
mortality, especially among immunosuppressed patients, and antifungal therapy is critical to …

Candida species belong to the normal microbiota of the oral cavity and gastrointestinal and
vaginal tracts, and are responsible for several clinical manifestations, from mucocutaneous …

The echinocandin class of antifungal agents is considered to be the first-line treatment of
bloodstream infections (BSI) due to Candida glabrata. Recent reports of BSI due to strains of …

Invasive candidiasis (IC) can affect individuals with various underlying diseases hospitalized
in different parts of hospitals. In recent decades, IC has caused 27–55% mortality in general …